Salarius Pharmaceuticals Inc Stock News

HOUSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (“Salarius” or the “Company”) today announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for and convened on December 19, 2025 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statem...

The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker “DCOY” effective in early January 2026 Company to focus on advancing lead antiviral programs, expanding platform validation and achieving multiple data milestones Strategic 2026 roadmap designed to accelerate development, expand pipeline breadth, and drive long-term sharehold...

Salarius subsidiary Decoy Therapeutics' influenza fusion inhibitors, designed using its proprietary IMP 3 ACT™ platform, show excellent in silico free energy binding to the viral target entry protein, supporting potential for anti-flu activity IMP 3 ACT's demonstrated capability to create a single antiviral therapeutic against influenza, COVID and RSV has potential to position Salarius to addre...

HOUSTON and CAMBRIDGE, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates that its common stock continues to trade uninterrupted on the Nasdaq Stock Market under the stock ticker “SLRX.

Strategic transaction supports the advancement of Decoy's rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP 3 ACT™ platform Combined company has pro forma cash of $14 million following merger and closing of recent public offering HOUSTON and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals (Nasdaq: SLRX) (“Salar...

HOUSTON , Nov. 11, 2025 /PRNewswire/ -- Salarius Pharmaceuticals, Inc. ("Salarius" or the "Company") (NASDAQ: SLRX) today announced the pricing of an underwritten public offering for gross proceeds of approximately $7 million before deducting underwriting discounts and commissions and other offering expenses. The offering is comprised of 2,514,335 shares of its common stock ("Common Stock") and...

HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on October 10, 2025 the Company received notice from the Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Standard Requirement. This follows the Company's announcement on September 9, 2025 that it had re...

HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on September 4, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Requirement.